New drug combo shows promise for tough HPV cancers in early trial
Disease control
Completed
This early-phase trial tested a new drug called TGN-S11, alone and combined with the immunotherapy Keytruda, in 28 patients with advanced HPV-related cancers that had come back or spread. The main goal was to find a safe dose and see how the body handles the drug. Results will he…
Phase: PHASE1 • Sponsor: Toragen, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:24 UTC